| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
RSV604 racemate targets the respiratory syncytial virus (RSV) nucleoprotein, which is essential for viral RNA replication and transcription. By binding to the nucleoprotein, the compound disrupts the viral RNA replication and transcription processes, thereby inhibiting RSV replication. The racemic mixture is less potent than the S-isomer, indicating that the antiviral activity is primarily associated with the S-enantiomer. The compound is used to study RSV polymerase targeting and mechanistic inhibition of viral transcription-replication coupling.
|
|---|---|
| ln Vitro |
In vitro studies have demonstrated that RSV604 racemate is an inhibitor of RSV replication. However, the racemic mixture is much less effective against RSV strains than the S-isomer. The compound acts by binding to the nucleoprotein, disrupting viral RNA replication and transcription. In vitro antiviral activity is assessed using RSV-infected cell cultures, where the compound's ability to reduce viral replication is measured. The racemate's lower potency compared to the S-isomer has been confirmed in multiple in vitro studies.
|
| ln Vivo |
In vivo studies on RSV604 racemate are limited. As a research compound, RSV604 racemate is used to study RSV replication and the mechanisms of viral transcription-replication coupling. However, specific in vivo efficacy data for the racemic mixture are not widely available in the published literature. The compound's S-isomer has been studied in animal models of RSV infection, but the racemate itself is primarily used as a research tool for in vitro studies and as a reference standard for enantiomer comparison.
|
| Enzyme Assay |
The in vitro antiviral assays for RSV604 racemate typically involve measuring the compound's ability to inhibit RSV replication in cell culture. In these assays, RSV-susceptible cell lines are infected with RSV and treated with varying concentrations of the compound. Viral replication is quantified using plaque reduction assays, RT-PCR, or immunofluorescence staining for viral proteins. The compound's potency is determined by calculating the EC50 or IC50 values. These assays are standard for characterizing the antiviral activity of RSV inhibitors.
|
| Cell Assay |
Cellular assays for RSV604 racemate are conducted using RSV-susceptible cell lines such as HEp-2 or A549 cells. Cells are infected with RSV and treated with varying concentrations of the compound. Viral replication is assessed by measuring viral RNA levels, viral protein expression, or plaque formation. Cell viability assays are performed to ensure that any observed antiviral effects are not due to cytotoxicity. These cell-based assays confirm the compound's antiviral activity and provide information about its potency and selectivity.
|
| Animal Protocol |
In vivo animal studies for RSV604 racemate are not well-documented in the available literature. The compound's S-isomer has been studied in animal models of RSV infection, but specific in vivo protocols for the racemic mixture have not been published. For similar RSV inhibitors, typical in vivo protocols involve the use of mouse or cotton rat models of RSV infection. The compound is administered by various routes, and antiviral efficacy is assessed by measuring viral load in lung tissues and clinical signs of infection.
|
| ADME/Pharmacokinetics |
RSV604 racemate has a molecular weight of 388.39 and a molecular formula of C22H17FN4O2. The compound appears as a white to off-white solid powder. For research use, RSV604 racemate is typically stored as powder at -20degC for up to 3 years or at 4degC for up to 2 years, and in solvent at -80degC for up to 1 year. The compound is soluble in DMSO and other appropriate solvents for in vitro assays. Detailed pharmacokinetic parameters such as oral bioavailability, half-life, and tissue distribution have not been determined for the racemic mixture.
|
| Toxicity/Toxicokinetics |
Toxicological data for RSV604 racemate are limited. As a research compound, RSV604 racemate has not been systematically evaluated for toxicity in preclinical studies. The compound is for research use only and not for human therapeutic use. Standard safety precautions should be followed when handling the compound, including the use of appropriate personal protective equipment. Researchers should consult the Safety Data Sheet (SDS) for specific safety information.
|
| References | |
| Additional Infomation |
RSV604 racemate (CAS#: 676128-62-4) is a racemic mixture of RSV604, an inhibitor of respiratory syncytial virus (RSV) replication. It has a molecular formula of C22H17FN4O2 and a molecular weight of 388.39. The compound acts by binding to the nucleoprotein, disrupting viral RNA replication and transcription. As a racemic mixture, it shows less potency against RSV strains compared to the S-isomer. RSV604 racemate is not approved for clinical use and is available only for research purposes in antiviral drug discovery and RSV biology.
|
| Molecular Formula |
C22H17N4O2F
|
|---|---|
| Molecular Weight |
388.39438
|
| Exact Mass |
388.133
|
| CAS # |
676128-62-4
|
| Related CAS # |
RSV604;676128-63-5;RSV604 (R enantiomer);932108-20-8
|
| PubChem CID |
5279171
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
575.0±50.0 °C at 760 mmHg
|
| Flash Point |
301.6±30.1 °C
|
| Vapour Pressure |
0.0±1.6 mmHg at 25°C
|
| Index of Refraction |
1.667
|
| LogP |
3.19
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
29
|
| Complexity |
634
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
MTPVBMVUENFFLL-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C22H17FN4O2/c23-16-11-5-7-13-18(16)25-22(29)27-20-21(28)24-17-12-6-4-10-15(17)19(26-20)14-8-2-1-3-9-14/h1-13,20H,(H,24,28)(H2,25,27,29)
|
| Chemical Name |
1-(2-fluorophenyl)-3-(2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl)urea
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~128.74 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.75 mg/mL (7.08 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 27.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.75 mg/mL (7.08 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 27.5 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5747 mL | 12.8737 mL | 25.7473 mL | |
| 5 mM | 0.5149 mL | 2.5747 mL | 5.1495 mL | |
| 10 mM | 0.2575 mL | 1.2874 mL | 2.5747 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
